CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

CytoDyn is actually  a   biotech which has proved helpful vigilantly but unsuccessfully to develop an one off therapy, variously named Pro 140, leronlimab, as well as Vyrologix.

In development of this particular therapy, CytoDyn has cast its net wide and far both geographically and in terminology of prospective indications.

CytoDyn’s inventories of leronlimab are building up, whether they will ever be being used is actually an open question.

While CYDY  has been dawdling, promote opportunities for leronlimab as being a combination treatment in the curing of multi-drug-resistant HIV are actually closing.

I’m writing my fifteenth CytoDyn (OTCQB:CYDY) guide on FintechZoom to celebrate the sale made of my past several shares. My first CytoDyn article, “CytoDyn: What to be able to Do When It’s Too Good to be able to Be True?”, set out what follows prediction:

Instead I expect it to be a serial disappointer. CEO Pourhassan presented such a highly marketing picture in the Uptick Newswire job interview which I came away with a poor opinion of the business.

Irony of irony, the poor impression of mine of the business has grown steadily, yet the disappointment has not been financial. Two years ago CytoDyn was trading <$1.00. On 2/19/20 as I create, it trades at $5.26; the closing transaction of mine was on 2/11/21 > $6.00.

What manner of stock  is this that delivers a > six bagger yet still disappoints? Therein sits the story; permit me to explain.

CytoDyn acquired its much-storied therapy (which I shall refer to as leronlimab) returned throughout 2012, announced as follows:

CytoDyn Inc…. has finished the acquisition of Pro 140, an experimental humanized monoclonal antibody (MAB) looking for the CCR5 receptor for your therapy as well as avoidance of HIV, from Progenics Pharmaceuticals, Inc. of Tarrytown, NY. Pro 140 is actually a late Stage II clinical growth mAb with demonstrated anti-viral activity in HIV- infected subjects. Today’s transaction of $3.5 zillion transfers ownership of this expertise as well as associated intellectual property coming from Progenics to CytoDyn, and also approximately 25 million mg of majority drug substance…. milestone payments after commencement of a stage III clinical trial ($1.5 huge number of) and also the first new drug application endorsement ($5 million), as well as royalty payments of 5 % of net sales after commercialization.

Since that moment, CytoDyn’s helping nous, Nader Pourhassan [NP] has turned this inauspicious acquisition right into a springboard for CytoDyn to purchase a market cap > $3.5 billion. It has done so in premium reliance on leronlimab.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News
CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

As opposed to having a pipeline with many indications and numerous therapies, it’s this single treatments in addition to a “broad pipeline of indications” because it places it. I call some pipelines, “pipedots.” In CytoDyn’s case it touts its leronlimab as a potentially beneficial therapy of dozens of indications.

Its opening banner on the website of its (below) shows an active company with diverse interests albeit centered on leronlimab, multiple illness types, multiple publications in addition to multiple presentations.

Can it all be smoke cigarettes and mirrors? That is a question I’ve been asking myself from the very start of my interest in this company. Judging by the multiples of thousands of various commentary on listings accessible through Seeking Alpha’s CytoDyn Summary page, I am a lot from alone in this particular question.

CytoDyn is a classic battleground, or even some could say cult inventory. Its adherents are fiercely shielding of its prospects, quick to label any bad opinions as scurrilous short mongering.

CytoDyn Inc. (CYDY) Stock Price Today, Quote & News

 

Related Post